Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine in combination with carboplatin (AUC2) - 21 days for reimbursement as a treatment option for the treatment of locally recurrent metastatic triple negative breast cancer.

This is written in the approval document as:

Treatment of locally recurrent metastatic triple negative breast cancer.

Citation

Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days, 2023, version number 5, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/430-gemcitabine-and-carboplatin-auc2-therapy-21-days.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine